412859bb-8b2a-44bf-b3b2-6acd30986067
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- E2F_TARGETS+0.500
- MYC_TARGETS_V1+0.500
- ALLOGRAFT_REJECTION+0.300
- G2M_CHECKPOINT+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- DNA_REPAIR+0.200
- SPERMATOGENESIS+0.200
- INTERFERON_ALPHA_RESPONSE+0.100
- INTERFERON_GAMMA_RESPONSE+0.100
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- HEME_METABOLISM-0.400
- PROTEIN_SECRETION-0.400
- TGF_BETA_SIGNALING-0.400
- UV_RESPONSE_DN-0.400
- ANGIOGENESIS-0.300
- APICAL_SURFACE-0.300
- CHOLESTEROL_HOMEOSTASIS-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- HYPOXIA-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 98e3beb5-bff2-4c4e-b492-c4ed7dda9d9c | — | — | 0.871 |
| 2 | TCGA-BH-A0B9-01A-11R-A056-07 | — | E | 0.871 |
| 3 | NB4_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.869 |
| 4 | SRR8518297 | — | E | 0.862 |
| 5 | TCGA-58-8387-01A-11R-2296-07 | — | cohortSQ2 | 0.860 |
| 6 | MOLM13_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.852 |
| 7 | BS_MMNRZ1EQ | ATRT | — | 0.850 |
| 8 | TCGA-DK-AA6T-01A-11R-A39I-07 | — | — | 0.850 |
| 9 | TCGA-OL-A5D7-01A-11R-A27Q-07 | — | E | 0.844 |
| 10 | C3N-03080 | — | cohortSQ1 | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |